Navigation Links
Peramivir in Medical News

BioCryst Reports Positive Results From a Phase 2 Study of Intravenous Peramivir for Outpatient Influenza

A Single Dose of Peramivir is Effective and Well-Tolerated at Both 300 mg and 600 mg Dose Levels BIRMINGHAM, Ala., Oct. 28 /PRNewswire-FirstCall/ -- BioCryst Pharmaceuticals, Inc. (Nasdaq: BCRX ) today announced that a double-blind, placebo-controlled, Phase 2 study of intravenous (i.v.) pe...

BioCryst Reports Second Quarter 2009 Financial Results And Provides Corporate Update

... and potential emergency use of intravenous (i.v.) peramivir in the U.S. "Our efforts at BioCryst remain focused on moving our leading peramivir and forodesine clinical development programs forwa...iligently with government agencies to provide i.v. peramivir as a potential treatment option for an influenza e...

BioCryst to Present at the 11th Annual BIO CEO & Investor Conference

...at many subjects in the Phase 2 clinical trials of peramivir did not receive adequate dosing by intramuscular i...ndition, reduce or eliminate future funding of the peramivir program, that ongoing peramivir clinical trials may not be successful, that the...

BioCryst Pharmaceuticals to Announce Fourth Quarter and Year End 2008 Financial Results on February 6, 2009

...at many subjects in the Phase 2 clinical trials of peramivir did not receive adequate dosing by intramuscular i...ndition, reduce or eliminate future funding of the peramivir program, that ongoing peramivir clinical trials may not be successful, that the...

BioCryst to Present at the Rodman and Renshaw 10th Annual Healthcare Conference

...at many subjects in the Phase 2 clinical trials of peramivir did not receive adequate dosing by intramuscular i...ndition, reduce or eliminate future funding of the peramivir program, that ongoing peramivir clinical trials may not be successful, that the pe...

BioCryst Pharmaceuticals to Announce First Quarter 2008 Financial Results on May 8, 2008

...ear contract to BioCryst to advance development of peramivir to treat seasonal and life-threatening influenza. ...t many subjects in the Phase II clinical trials of peramivir did not receive adequate dosing by intramuscular i...ndition, reduce or eliminate future funding of the peramivir program, that the...

BioCryst to Release Third Quarter 2007 Financial Results on Thursday, November 8, 2007

...r contract to BioCryst for advanced development of peramivir to treat seasonal and life-threatening influenza. ...t many subjects in the Phase II clinical trials of peramivir did not receive adequate dosing by i.m. injection ...be correct, that final results and analysis of the peramivir Phase II trial may differ from the preliminary res...

BioCryst’s Bird Flu Drug Enjoys Fast-Track Review By FD

...n have a new form of anti-viral therapy to effectively manage the bird flu threat. "The FDA's decision supports our belief in the potential of peramivir as an effective therapy for the treatment of influenza, including highly virulent, life-threatening strains like those associated with avian influenza...
Peramivir in Medical Technology

BioCryst Pharmaceuticals Reports Positive Results of Shionogi & Co. Sponsored Phase 3 Studies of i.v. Peramivir for Influenza

BIRMINGHAM, Ala., July 17 /PRNewswire-FirstCall/ -- BioCryst Pharmaceuticals (Nasdaq: BCRX ) today announced positive results from two Phase 3 studies of intravenous (i.v.) peramivir in patients with seasonal influenza. The studies were sponsored by BioCryst's partner Shionogi & Co.,...

BioCryst Provides Peramivir Update and Reports First Quarter 2009 Financial Results

BIRMINGHAM, Ala., May 8 /PRNewswire-FirstCall/ -- BioCryst Pharmaceuticals, Inc. (Nasdaq: BCRX ) today announced that, based on discussions with the U.S. Department of Health and Human Services/Biomedical Advanced Research and Development Authority (HHS-BARDA), it is preparing a portion of its i...

BioCryst Pharmaceuticals to Announce Peramivir Update and First Quarter 2009 Financial Results on May 8, 2009

BIRMINGHAM, Ala., May 7 /PRNewswire-FirstCall/ -- BioCryst Pharmaceuticals (Nasdaq: BCRX ) today announced that an update regarding peramivir and its first quarter 2009 financial results will be released on Friday, May 8, 2009. Following the release, BioCryst will host a conference call and Web...

Data from Phase 2 Study of Peramivir in Patients Hospitalized with Influenza Presented at the XI International Symposium on Respiratory Viral Infections

BIRMINGHAM, Ala., Feb. 23 /PRNewswire-FirstCall/ -- BioCryst Pharmaceuticals (Nasdaq: BCRX ) today announced that the full data set from an exploratory Phase 2 study of peramivir in patients hospitalized for influenza was presented by the study's Principal Investigator, Dr. Michael G. Ison, Assi...

BioCryst Reports Positive Preliminary Results of a Shionogi & Co., Ltd. Sponsored Phase II Study of I.V. Peramivir for the Treatment of Influenza in the Outpatient Setting

BIRMINGHAM, Ala., July 28 /PRNewswire-FirstCall/ -- BioCryst Pharmaceuticals, Inc. (Nasdaq: BCRX ) today announced preliminary results of a Phase II study of intravenous (i.v.) peramivir administered via a single dose injection in the outpatient setting for the treatment of seasonal influenza...

BioCryst Announces Initiation of Phase II Study of Intramuscular Peramivir for the Treatment of Seasonal Influenza

BIRMINGHAM, Ala., July 10 /PRNewswire-FirstCall/ -- BioCryst Pharmaceuticals, Inc. (Nasdaq: BCRX ) today announced the initiation of a Phase II study of intramuscular (i.m.) peramivir for the treatment of seasonal influenza. The double-blind, placebo-controlled, parallel group Phase II tria...

BioCryst Updates Peramivir Clinical Development Plan

BIRMINGHAM, Ala., Jan. 23 /PRNewswire-FirstCall/ -- BioCryst Pharmaceuticals, Inc. (Nasdaq: BCRX ) today provided an update on activities conducted following release of the preliminary Phase II data and outlined the resulting clinical development plan for intramuscular (i.m.) peramivir. (Lo...

St. Jude Study Shows Effectiveness of Peramivir in Prevention of Mortality in Mouse Model of Avian Influenza H5N1 Virus Infection

BioCryst Says Study Confirms and Extends Evidence Seen in a Previous Study BIRMINGHAM, Ala., May 02, 2007 /PRNewswire-FirstCall/ -- BioCryst Pharmaceuticals, Inc. today announced that investigators at St. Jude Children's Research Hospital, Memphis, TN, reported favorable results evaluating peramiv...

BioCryst Presents Phase I Peramivir Data at the Options for the Control of Influenza Conference

Pharmacokinetic and Safety Profile of the Intramuscular Formulation of Peramivir Supports Further Evaluation as Treatment for Acute Influenza BIRMINGHAM, Ala., June 18, 2007 /PRNewswire-FirstCall/ -- BioCryst Pharmaceuticals, Inc. presented results from two Phase I clinical studies of an intramusc...

Data Presented at 2007 ASH Meeting Demonstrate Activity of Forodesine HCl as a Single Agent or in Combination With Bendamustine in Certain Types of Leukemia and Lymphoma

...r contract to BioCryst for advanced development of peramivir to treat seasonal and life-threatening influenza. ...t many subjects in the Phase II clinical trials of peramivir did not receive adequate dosing by i.m. injection ...be correct, that final results and analysis of the peramivir Phase II trial may differ from the preliminary res...
Peramivir in Biological News

Peramivir protects mice from lethal H5N1 infection

... The antiviral drug peramivir might offer humans significant protection during a...day versus eight days); route of administration of peramivir (intramuscular injections alone versus intramuscul...ice). In all cases, the investigators administered peramivir to mice one hour after nasally administering a let...
Peramivir in Biological Technology

BioCryst Reports Preliminary Results From a Phase II Clinical Trial of Peramivir in Subjects With Acute Influenza

BIRMINGHAM, Ala., Sept. 19 /PRNewswire-FirstCall/ -- BioCryst Pharmaceuticals, Inc. (Nasdaq: BCRX ) today announced preliminary findings from a Phase II study with intramuscular (i.m.) injection of peramivir, the Company's product candidate for the treatment of seasonal and life-threatening i...

BioCryst Reports Fourth Quarter and Year End 2008 Financial Results and Provides Corporate Update

... in clinical development costs associated with the peramivir program, a reduction in manufacturing costs associated with both the peramivir and Forodesine HCl programs and a reduction in cos...red in the Phase 3 program of intramuscular (i.m.) peramivir for outpatient influenza. The Company initiated t...

BioCryst to Present at the J.P. Morgan 27th Annual Healthcare Conference

...at many subjects in the Phase 2 clinical trials of peramivir did not receive adequate dosing by intramuscular i...ndition, reduce or eliminate future funding of the peramivir program, that ongoing peramivir clinical trials may not be successful, that the...

BioCryst to Present Three Posters During the 50th American Society of Hematology Annual Meeting and Exposition

...at many subjects in the Phase 2 clinical trials of peramivir did not receive adequate dosing by intramuscular i...ndition, reduce or eliminate future funding of the peramivir program, that ongoing peramivir clinical trials may not be successful, that the...

BioCryst Reports Third Quarter 2008 Financial Results and Provides Corporate Update

...0, 2007. This decrease is driven by a reduction in peramivir clinical development costs and associated revenue ... in clinical development costs associated with the peramivir program, a reduction in manufacturing costs associated with both the peramivir and forodesine HCl program and a reduction in cost...

BioCryst Reports Results From the First-Ever Completed Active-Controlled Phase 2 Study in Hospitalized Influenza

...ty of five days of therapy with either 200 mg i.v. peramivir per day, 400 mg i.v. peramivir per day or 75 mg oral oseltamivir twice a day, in ...ficacy endpoints between the three treatment arms. peramivir was generally safe and well-tolerated at these dos...

BioCryst Pharmaceuticals To Announce Third Quarter 2008 Financial Results On October 31, 2008

...t many subjects in the Phase II clinical trials of peramivir did not receive adequate dosing by intramuscular i...ndition, reduce or eliminate future funding of the peramivir program, that ongoing peramivir clinical trials may not be successful, that the pe...

Peramivir Phase 2 Data for the Treatment of Outpatient Influenza to be Presented at the 48th Annual Interscience Conference on Antimicrobial Agents and Chemotherapy

...ble-Blind, Placebo-Controlled Study of Intravenous peramivir in Acute Influenza Patients" (Poster Session # 302...y and Pharmaceutical Sciences. About Peramivir peramivir is an antiviral agent that inhibits the interactio...d of influenza within a host. In laboratory tests, peramivir has shown activity against viral strains that are ...

BioCryst to Present at the JMP Healthcare Focus Conference

...t many subjects in the Phase II clinical trials of peramivir did not receive adequate dosing by intramuscular i...ndition, reduce or eliminate future funding of the peramivir program, that ongoing peramivir clinical trials may not be successful, that the pe...

BioCryst to Present at UBS 2008 Global Life Sciences Conference

...t many subjects in the Phase II clinical trials of peramivir did not receive adequate dosing by intramuscular i...ndition, reduce or eliminate future funding of the peramivir program, that ongoing peramivir clinical trials may not be successful, that the pe...
Other Tags
(Date:9/2/2015)... MD (PRWEB) , ... September 02, 2015 , ... ... the ambulatory healthcare industry announced today the launch of its enhanced, cloud-based mobile ... RxNT’s “new look” and focus on improving prescriber usability. A leader in health ...
(Date:9/2/2015)... ... September 02, 2015 , ... ... intermediate or final products. Automating sample handling makes density measurements more efficient and ... each step of the automated workflow and the advantages compared to manual sample ...
(Date:9/2/2015)... , ... September 02, 2015 , ... ... clinical and academic partnership has earned international recognition as a premier center for ... that can cause sudden, catastrophic internal bleeding and stroke. , Cure HHT, ...
(Date:9/2/2015)... (PRWEB) , ... September 02, 2015 , ... Ericson is ... CDI Education Director for HCPro and Associate Director of Education for the Association for ... Advancing CDI and ICD-10 for CDI Boot Camps. She serves as a CDI subject ...
(Date:9/2/2015)... IL (PRWEB) , ... September 02, 2015 , ... ... is officially announced today. The two day international investment and business conference will ... Oct 9-11, 2015 in Beijing China. The full-weekend networking conference will feature leading ...
Breaking Medicine News(10 mins):Health News:RxNT Releases Enhanced ePrescribing iPhone App to Improve Prescriber Usability 2Health News:New Video from METTLER TOLEDO Shows the Advantages of Sample Handling Automation in Density Determination 2Health News:New Video from METTLER TOLEDO Shows the Advantages of Sample Handling Automation in Density Determination 3Health News:UPMC-University of Pittsburgh Named Center of Excellence for Rare Disorder 2Health News:UPMC-University of Pittsburgh Named Center of Excellence for Rare Disorder 3Health News:UPMC-University of Pittsburgh Named Center of Excellence for Rare Disorder 4Health News:ezDI Names Noted CDI Educator Cheryl Ericson as Company’s Clinical Documentation Manager 2Health News:ezDI Names Noted CDI Educator Cheryl Ericson as Company’s Clinical Documentation Manager 3Health News:ezDI Names Noted CDI Educator Cheryl Ericson as Company’s Clinical Documentation Manager 4Health News:The 2015 China Overseas Investment and Entrepreneurship Summit (COIES) Announced 2
(Date:8/5/2015)... MOUNTAIN VIEW, Calif. , Aug. 5, 2015 /PRNewswire/ ... it exhibits continuous growth in applications, penetration into newer ... year after year. The global biosensors space has seen ... having exited the market so far. (Photo ... from Frost & Sullivan, Analysis of the Global ...
(Date:8/4/2015)... Aug. 4, 2015  AMRI (NASDAQ: AMRI ) today reported ... 2015. Highlights: , Second quarter contract revenue ... 2014 , Adjusted contract margins of ... $0.22, including a $0.05 decrease in EPS from royalties in the ... million "We are very pleased to present another ...
(Date:7/31/2015)... SHENZHEN , Kina, 31. juli 2015 ... ) bliver afholdt af BGI fra den 22. - 25. ... Konferencen fejrer sin 10-års fødselsdag i år. ... verdens mest indflydelsesrige årlige møder på ,omik,-feltet, og er ... forsamlinger. ICG-10 fokuserer på nylige gennembrud ...
Breaking Biology News(10 mins):Innovative Biosensors Incite Use in Non-Traditional Applications 2Innovative Biosensors Incite Use in Non-Traditional Applications 3Innovative Biosensors Incite Use in Non-Traditional Applications 4AMRI Announces Second Quarter 2015 Results 2AMRI Announces Second Quarter 2015 Results 3AMRI Announces Second Quarter 2015 Results 4AMRI Announces Second Quarter 2015 Results 5AMRI Announces Second Quarter 2015 Results 6AMRI Announces Second Quarter 2015 Results 7AMRI Announces Second Quarter 2015 Results 8AMRI Announces Second Quarter 2015 Results 9AMRI Announces Second Quarter 2015 Results 10AMRI Announces Second Quarter 2015 Results 11AMRI Announces Second Quarter 2015 Results 12AMRI Announces Second Quarter 2015 Results 13AMRI Announces Second Quarter 2015 Results 14AMRI Announces Second Quarter 2015 Results 15AMRI Announces Second Quarter 2015 Results 16AMRI Announces Second Quarter 2015 Results 17AMRI Announces Second Quarter 2015 Results 18AMRI Announces Second Quarter 2015 Results 19AMRI Announces Second Quarter 2015 Results 20AMRI Announces Second Quarter 2015 Results 21AMRI Announces Second Quarter 2015 Results 22AMRI Announces Second Quarter 2015 Results 23AMRI Announces Second Quarter 2015 Results 24Den 10. internationale konference om Genomics (ICG-10) åbner i oktober 2
Other Contents